Calendrier des promotions AusCann Group Holdings Ltd
Calendrier avancé
Graphique simple
À propos de l'entreprise
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. plus de détails| EBITDA | -0.0051 |
|---|---|
| EV/EBITDA | -6.99 |
| Industry | Pharmaceuticals |
| P/BV | 1.7 |
| P/S | 105.75 |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Выручка | 0.000671 |
| Сайт | https://auscann.com.au |
| Цена ао | 0.0038 |
| Changement de prix par jour: | 0% (0.0038) |
|---|---|
| Changement de prix par semaine: | 0% (0.0038) |
| Changement de prix par mois: | 0% (0.0038) |
| Changement de prix sur 3 mois: | 0% (0.0038) |
| Changement de prix sur six mois: | -68.33% (0.012) |
| Changement de prix par an: | +90% (0.002) |
| Evolution du prix sur 3 ans: | -94.63% (0.0708) |
| Evolution du prix sur 5 ans: | -97.74% (0.168) |
| Evolution des prix sur 10 ans: | 0% (0.0038) |
| Evolution des prix depuis le début de l'année: | 0% (0.0038) |
|
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
|||||||||||||||||||||||||||||||||||||
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
|---|---|---|---|
| Mr. Christopher Mews A.C.I.S., B. Bus, C.P.A. | Chief Financial Officer | ||
| Ms. Rachel Jelleff Kerr | Company Secretary |
Adresse: Australia, West Perth, 1202 Hay Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://auscann.com.au
Site web: https://auscann.com.au
